Paratek Pharmaceuticals : Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock

BOSTON, June 22, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the pricing of its underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $13.00 per share, before underwriting discounts and commissions. All of the shares of common stock to be sold in the offering will be sold by Paratek. In addition, Paratek has granted to the underwriters a 30-day option to purchase up to 637,500 additional shares of its common stock.

Leerink Partners and Guggenheim Securities acted as joint book-running managers. Ladenburg Thalmann and BTIG acted as co-managers.

Net proceeds to Paratek from the shares of common stock to be sold by Paratek in the offering are expected to be approximately $51.4 million, after deducting underwriting discounts and commissions and estimated offering expenses, but excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about June 27, 2016, subject to customary closing conditions.

The offering was made pursuant to a shelf registration statement declared effective by the Securities and Exchange Commission (the 'SEC') on April 27, 2015. A preliminary prospectus supplement related to the offering was filed with the SEC on June 20, 2016, and a final prospectus supplement related to the offering will be filed with the SEC.

Copies of the prospectus for this offering may be obtained, when available, by contacting Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, email: Syndicate@Leerink.com, phone: (800) 808-7525 ext. 6142; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave, 8th Floor, New York, NY 10017, email: GSEquityProspectusDelivery@guggenheimpartners.com, phone: (212) 518-9658.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Forward-Looking Statements
This press release includes forward-looking statements, including statements relating to the underwritten public offering. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Paratek cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Applicable risks and uncertainties include those identified under the heading 'Risk Factors' included in Paratek's shelf registration statement declared effective by the SEC on April 27, 2015, the preliminary prospectus supplement related to the proposed offering filed with the SEC on June 20, 2016 and Paratek's Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Paratek assumes no duty to update forward-looking statements.

CONTACTS:
Media:
Michael Lampe
Scient Public Relations
(484) 575-5040
michael@scientpr.com

Investors
Hans VitzthumLifeSci Advisors, LLC.
212-915-2568

Paratek Pharmaceuticals